Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A1 | P43005 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 4/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9725660 | 1.00 | SLC1A1 (0.40) | SLC1A1LTA4HCA12CA14DGAT1 | |
| SCHEMBL3730273 | 1.00 | SLC1A1 (0.40) | SLC1A1LTA4HCA12CA14DGAT1 | |
| Hydrochloric Acid SCHEMBL1143881 | 0.98 | SLC1A1 (0.39) | SLC1A1LTA4HCA12CA14DGAT1 | |
| Hydrochloric Acid SCHEMBL25409265 | 0.98 | SLC1A1 (0.39) | SLC1A1LTA4HCA12CA14DGAT1 | |
| Hydrochloric Acid SCHEMBL3364146 | 0.98 | SLC1A1 (0.39) | SLC1A1LTA4HCA12CA14DGAT1 | |
| SCHEMBL18477 | 0.89 | LTA4H (0.43) | SLC1A1LTA4HCYP2D6NOS1MEN1 | |
| SCHEMBL1841835 | 0.89 | LTA4H (0.43) | SLC1A1LTA4HCYP2D6NOS1MEN1 | |
| SCHEMBL1654337 | 0.89 | LTA4H (0.43) | SLC1A1LTA4HCYP2D6NOS1MEN1 | |
| Water SCHEMBL3912787 | 0.87 | LTA4H (0.42) | SLC1A1LTA4HCYP2D6NOS1MEN1 | |
| SCHEMBL6893763 | 0.87 | LTA4H (0.42) | SLC1A1LTA4HCYP2D6NOS1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117030911-A | Purity detection method of 5- (tertiary butyl) 1-methyl L-glutamic acid | 上海吉奉生物科技有限公司 | 2023-11-10 | — | — | CN | claimed |
| US-20240208968-A1 | ALPHA V BETA 6 AND ALPHA V BETA 1 INTEGRIN INHIBITORS AND USES THEREOF | DICE MOLECULES SV, INC. | 2024-06-27 | — | — | US | disclosed |
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | AZEVAN PHARMACEUTICALS, INC. (US) | 2024-04-11 | — | — | US | disclosed |
| CN-117030911-A | Purity detection method of 5- (tertiary butyl) 1-methyl L-glutamic acid | 上海吉奉生物科技有限公司 | 2023-11-10 | — | — | CN | disclosed |
| CN-117030911-A | Purity detection method of 5- (tertiary butyl) 1-methyl L-glutamic acid | 上海吉奉生物科技有限公司 | 2023-11-10 | — | — | CN | disclosed |
| WO-2023161878-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR FOLATE RECEPTOR-EXPRESSING CELLS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-08-31 | — | — | WO | disclosed |
| CN-116327950-A | Use of a composition for the treatment of neuropsychiatric symptoms of neurodegenerative diseases | 阿泽范药品公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-116139282-A | Compositions and methods for treating neurodegenerative diseases | 阿泽范药品公司 | 2023-05-23 | — | — | CN | disclosed |
| US-20230123729-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | AZEVAN PHARMACEUTICALS INC (US) | 2023-04-20 | — | — | US | disclosed |
| US-11628160-B2 | Compositions and methods for treating brain injury | AZEVAN PHARMACEUTICALS, INC. (US) | 2023-04-18 | — | — | US | disclosed |
| US-20040006093-A1 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2004-01-08 | — | — | US | disclosed |
| US-6583139-B1 | Treatment of inflammatory diseases; inflammatory brain diseases such as multiple sclerosis; N-(Toluene-4-sulfonyl)-L-prolyl-4-(alpha -methylbenzyloxy)-L-phenylalanine; Very Late Antigen 4 | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2003-06-24 | — | — | US | disclosed |
| US-6420427-B1 | PREVENTION AND/OR TREATMENT OF RHEUMATOID DISEASES, ARTHROSTEITIS, UNUSUAL BONE RESORPTION, OSTEOPOROSIS, PERIODONTITIS, INTERSTITIAL NEPHRITIS, ARTERIOSCLEROSIS, PULMONARY EMPHYSEMA, CIRRHOSIS, CORNEA INJURY | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-07-16 | — | — | US | disclosed |
| CN-1318069-A | Factor VIIa inhibitors | AVENTIS PHARMA DEUTSHLAND GMBH (DE) | 2001-10-17 | — | — | CN | disclosed |
| US-6287794-B1 | Factor Vlla inhibitors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-09-11 | — | — | US | disclosed |
| EP-1114061-A1 | FACTOR VIIa INHIBITORS | Aventis Pharma Deutschland GmbH (DE) | 2001-07-11 | — | — | EP | disclosed |
| CN-1282319-A | Aminobutanoic acid derivatives | ONO PHARMACEUTICAL CO (JP) | 2001-01-31 | — | — | CN | disclosed |
| EP-1024134-A1 | AMINOBUTANOIC ACID DERIVATIVES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2000-08-02 | — | — | EP | disclosed |
| WO-2000015658-A1 | FACTOR VIIa INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-03-23 | — | — | WO | disclosed |
| EP-0987274-A1 | Factor VIIa Inhibitors | Hoechst Marion Roussel Deutschland GmbH (DE) | 2000-03-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208968-A1 | ALPHA V BETA 6 AND ALPHA V BETA 1 INTEGRIN INHIBITORS AND USES THEREOF | ITGB1, ITGA1, ITGAV | SLC1A1 3740/4885LTA4H 666/4885CA12 2865/4885 |
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | FABP7, PYGB, CHAT | SLC1A1 1024/4885LTA4H 927/4885CA12 145/4885 |
| US-20230123729-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | HTT, AVPR2, AVPR1B | SLC1A1 337/4885LTA4H 1747/4885CA12 2914/4885 |
| US-20040006093-A1 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, CD4 | SLC1A1 508/4885LTA4H 15/4885CA12 2790/4885 |
| US-11628160-B2 | Compositions and methods for treating brain injury | FABP7, PYGB, CHAT | SLC1A1 1024/4885LTA4H 927/4885CA12 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.